ClinicalThought™
Interact with experts and peers.

Recent Posts

10 of 55 Shown
  • Weighing the Treatment Options for Genotype 3 HCV Infection in Cirrhotics

    Mark S. Sulkowski MD - 2/25/2016 3 comments / Last Comment: 4/11/2016
    In my practice, it is the patient with cirrhosis and genotype 3 HCV infection who causes me to pause and carefully consider the patient’s treatment options.
  • How I Manage Patients With HCV After DAA Treatment Failure

    Jordan J. Feld MD, MPH - 1/19/2016 5 comments / Last Comment: 4/22/2016
    In the few HCV patients for whom DAA treatment fails, I consider a combination of 2 or more of the following: switching to a different DAA class, treating for longer, or adding ribavirin.
  • Decompensated Cirrhosis: My Take on New Treatment Strategies Following AASLD 2015

    Ira M. Jacobson MD - 12/24/2015 2 comments / Last Comment: 1/4/2016
    Despite the variety of highly effective, highly tolerable regimens available for treating HCV, strategies for patients with decompensated liver disease remain challenging.
  • How I Use Resistance Testing to Guide Management of Patients With Chronic Hepatitis C

    Mark S. Sulkowski MD - 9/15/2015 12 comments / Last Comment: 3/8/2016
    Using a recent case patient, I outline my current approach to using HCV resistance testing to select therapy in patients who have previously received an HCV NS5A inhibitor.
  • My Evolving Strategy for Treating Patients With Genotype 3 HCV Infection

    Norah Terrault MD, MPH - 9/10/2015 9 comments / Last Comment: 6/5/2016
    Following the recent FDA approval of daclatasvir and the presentation of key data at the 2015 EASL meeting, our team has made several changes to our approach in managing patients with genotype 3 HCV infection.
  • Patients With Renal Disease: One of the Remaining Challenges in HCV Therapy

    Nancy Reau MD - 8/25/2015 30 comments / Last Comment: 5/1/2016
    A recent patient discussion highlighted important questions about how to approach HCV infection in renal disease.
  • How I Expect Evolving Options for HCV Therapy Will Affect Posttransplant Management

    Paul Y. Kwo MD - 7/29/2015 1 comment / Last Comment: 10/10/2015
    Will we finally have options to prevent posttransplantation HCV recurrence across the spectrum of genotypes?
  • Post-EASL Update: Is It Time to Use Resistance Testing to Guide HCV Treatment Decisions?

    Jordan J. Feld MD, MPH - 7/28/2015 5 comments / Last Comment: 12/6/2015
    With the highly effective DAA regimens now available for treating patients with HCV, fewer patients experience treatment failure. Could pretreatment-resistance testing help to decrease failures even further?
  • My Take on New Guidance for Treating Genotype 1 HCV–Infected Patients With Decompensated Cirrhosis

    Norah Terrault MD, MPH - 5/5/2015 3 comments / Last Comment: 7/26/2015
    We now have safe and effective treatment options for HCV infection in patients with decompensated cirrhosis. But how do ribavirin tolerability and treatment experience factor into how they should be used?
  • When Should Patients on the Liver Transplant Waitlist Receive HCV Therapy?

    John Roberts MD - 4/24/2015 4 comments / Last Comment: 6/26/2015
    Now that highly tolerable, highly effective HCV treatments are available, treatment in the pretransplant setting is a viable approach for many patients currently on the waitlist. Does this approach have a downside?
10 of 55 Shown
Show 10 More
Loading...